A glioma is a specific kind of tumour that emerges from glial stem cells or precursor cells within the central nervous system. These glial cells are a prevalent cell type found throughout the nervous system. While gliomas typically form within the brain, they rarely impact the spinal cord. Categorizing gliomas involves intricate factors, including genetic alterations (mutations) that are thought to contribute to tumour development, as well as the tumour’s microscopic characteristics (histologic classification). The concept of “differentiation” pertains to the cell’s specialized function, which holds vital importance in determining the histologic classification of gliomas.
The global glioma treatment market was valued at US$ 4,567.8 Million in 2022 and is anticipated to reach US$ 7,008.7 Million by the end of 2030 with a CAGR of 5.5% from 2023 to 2030 (forecast period).
Gliomas are classified into various grades, where grade 4 represents the most perilous and least specialized form, while grade 1 stands as the least risky and most specialized type. Some grade 3 gliomas acquire names based on the loss of structure, referred to as anaplasia. Gliomas categorized as grades 1 and 2 are commonly termed low-grade gliomas, whereas grades 3 and 4 are recognized as more dangerous gliomas.
The treatment of gliomas often involves a combination of radiation therapy, chemotherapy, and neurosurgical procedures. Medications prescribed for individuals with gliomas may encompass anti-epileptic drugs if seizures are experienced, anti-coagulants if blood clots form and corticosteroids to alleviate neurological symptoms arising from the fluid buildup around the tumour (peritumoral edema).
Glioma Treatment Market to Recover Amid COVID-19 Pandemic
The global market for glioma treatments has faced adverse effects due to the outbreak of the COVID-19 pandemic. Governments in affected countries issued mandates to postpone non-essential medical procedures and patient appointments. In the context of the pandemic, the field of surgical neuro-oncology encountered significant challenges in maintaining surgical treatments. The pandemic compelled the suspension of surgical neuro-oncology services as crucial ICU resources, including ventilators, personal protective equipment, and medical staff, were redirected to attend to COVID-19 patients. Consequently, there was a disruption in the availability of appropriate medical care for critically ill cancer patients. Individuals with glioblastoma, being susceptible to the COVID-19 virus, experienced setbacks in their scheduled surgeries and therapies. This led to a decline in year-over-year growth due to postponed brain surgeries at medical institutions and delayed outpatient surgical procedures.
Increasing Prevalence of High-grade Gliomas to Boost Glioma Treatment Market
High-grade gliomas are extremely perilous growths that primarily impact both children and adults. The market’s trajectory is expected to be influenced by a range of factors, encompassing frequent sessions of radiation therapy, erroneous brain surgeries, and a multitude of treatment approaches. Manufacturers are placing significant emphasis on integrating advanced technologies, with the anticipation that this will rapidly propel the sector forward. For instance, Kiyatec’s innovative ex vivo 3D cell culture method designed for high-grade gliomas is poised to receive novel clinical data at ASCO 2022. The industry is further fueled by an escalation in the frequency and occurrence of high-grade gliomas. Among the most prevalent brain tumours, high-grade gliomas constitute a major diagnosis. According to the National Library of Medicine, there is an estimated diagnosis rate of approximately 5.8 cases per 100,000 individuals annually for males and 4.1 cases for females in relation to high-grade gliomas.
North America to Spearhead the Glioma Treatment Market
North America is the fastest-growing segment in the glioma treatment market due to several factors, including:
- Increase in Approval of Novel Glioma Treatment Products: The regulatory landscape in North America is showing a positive trend towards facilitating the development and endorsement of products aimed at treating gliomas. Regulatory bodies are outlining clearer protocols and pathways for the approval of these emerging treatments, simplifying the process for pharmaceutical enterprises to introduce fresh products to the market.
- Heightened Prevalence of Brain Tumours: The frequency of brain tumour cases is on the rise across North America. For instance, data gathered by the American Society of Clinical Oncology (ASCO) indicates that approximately 23,820 individuals in the US were diagnosed with primary malignant brain and spinal cord tumours in 2018. Within this, brain tumours constituted 85% to 90% of all primary central nervous system malignancies.
- Increased Population Exposure to Radiation: The escalating exposure of the populace to potentially harmful radiation is elevating the risk of cancer occurrences. This significant factor is contributing to the expansion of the glioma treatment market in this geographical area.
- Presence of Prominent Industry Players: The notable presence of key industry players within North America has played a pivotal role in fostering the growth and advancement of the glioma treatment market in the region.
Companies operating in the glioma treatment market have adopted several growth strategies to expand their market share and increase their revenue. Some of the key players in the glioma treatment market include Thermo Fisher Scientific Inc., Emcure Pharmaceuticals Ltd., Sigma-Aldrich Co., Pfizer Inc., Taj Pharmaceuticals Limited, Novartis International AG, Teva Pharmaceutical Industries Ltd., GE Healthcare, Siemens Healthineers, Philips Healthcare, Shimadzu Corporation, Toshiba Medical Systems Corporation, Merck & Co., Inc., F. Hoffmann-Le Roche AG, Arbor Pharmaceuticals, LLC, Sun Pharmaceutical Industries, Ltd., Amneal Pharmaceuticals. LLC, AstraZeneca, Carestream Health, Hitachi Medical Corporation, and others.
- Strategic Partnerships and Collaborative Efforts: Within the realm of glioma treatment, enterprises are actively forming strategic partnerships and collaborative ventures. By pooling their expertise and resources, companies aim to accelerate the development of novel drugs for glioma treatment. These collaborations empower firms to capitalize on their individual strengths, fostering a more streamlined approach to developing innovative therapies. For instance, in January 2022, German pharmaceutical company ITM Isotope Technologies Munich SE joined forces with Helmholtz Zentrum München, the German Research Center for Environmental Health, to advance the clinical development of a radiopharmaceutical treatment targeting glioblastoma multiforme.
- Focusing on Product Innovation and Launches: Significant investments are being made in research and development efforts, aimed at creating novel glioma treatment drugs and enhancing existing products. This proactive stance leads to the introduction of new offerings into the market, thereby broadening the scope of product portfolios and gaining a competitive edge. An illustrative example comes from Theranostics, which received approval from the U.K.’s Medicines & Healthcare Products Regulatory Agency for its groundbreaking radiotherapeutic I-123 PARP therapeutic agent designed to address glioblastoma multiforme, both primary and recurrent, as of February 10, 2022.
- Geographical Expansion Initiatives: Market players are strategically expanding their footprint by venturing into untapped markets and establishing their presence in regions exhibiting substantial growth potential. This strategic move allows companies to tap into fresh customer segments and foster revenue growth.
- Mergers and Acquisitions for Enhanced Capabilities: Acquisitions and mergers have emerged as strategies to access new technologies, expertise, and product pipelines. This approach empowers companies to augment their capabilities and offerings, while also enhancing their market share.
- Elevating Brand Awareness through Marketing Efforts: Companies are investing in robust marketing and promotional campaigns to heighten awareness and educate both healthcare professionals and patients about the advantages associated with glioma treatment. These efforts play a pivotal role in boosting product demand and subsequently driving sales.
In Summary, these dynamic growth strategies collectively enable enterprises to extend their market reach, introduce innovative products, and ultimately bolster revenue within the ever-evolving landscape of glioma treatment.